Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galegenimab Extension Study in Geographic Atrophy
NCT04607148Phase 2Terminated
- Sponsor
- Genentech
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of galegenimab in geographic atrophy (GA), sponsored by Genentech. Started Nov 2020; status: terminated.
02
Drugs
galegenimab
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT04607148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607148.